GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Curative Biotechnology CUBT · USD

N/A · US listing · 🇺🇸 United States

Compare

0.83

0.00%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

—

FY2016FY2025

Net income

−$2.3m

FY2016FY2025

Free cash flow

−$868,870

FY2016FY2025

Shareholders' equity

−$6.1m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue—————————$11,091
Gross profit−$87,843−$92,213−$97,515−$7,955−$6,744−$5,301−$5,301−$5,301−$5,301$10,684
Research and development$6,569$14,027$269,782$2.5m$779,275—————
Operating income−$1.5m−$2.4m−$1.9m−$4.5m−$5.2m−$4.6m−$5,451−$5,451−$7,101−$1,518
Net income−$2.3m−$3.6m−$4.0m−$5.4m−$5.3m−$4.7m$331,953−$29,914−$22,983−$17,400
Diluted earnings per share-0.32-0.00-0.00-0.01-0.02-0.010.00-0.00-0.00-0.00

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$2.1m$2.2m$2.6m$2.1m$2.4m$2.3m$39,775$45,076$58,958$65,909
Cash and short-term investments$45,043$19,534$56,400$58,668$670,263$160,607————
Total liabilities$8.2m$7.1m$5.7m$22.6m$18.8m$6.8m$397,103$734,357$718,325$702,293
Debt$1.4m$1.4m$2.3m$1.1m—$559,761$125$198,767$198,617$198,467
Shareholders' equity−$6.1m−$4.9m−$3.1m−$2.5m$1.7m−$4.5m−$357,328−$689,281−$659,367−$636,384
Shares outstanding7m919m903m579m340m333m323m8m8m8m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$868,866−$1.0m−$486,585−$1.5m−$1.6m−$190,093−$150−$150−$150−$5,891
Capital spending−$4−$1−$14,041−$76,905−$21,334−$34,300−$6,834———
Free cash flow−$868,870−$1.0m−$500,626−$1.6m−$1.6m−$224,393−$6,984−$150−$150−$5,891

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Gross profit−$21,775−$21,776−$21,776−$21,775−$22,364−$21,928−$21,929−$21,928
Operating income−$373,016−$293,877−$54,973−$509,059−$669,899−$283,000−$673,000−$461,000
Net income−$608,907−$370,269−$289,603−$764,837−$710,147−$482,000−$903,000−$882,000
Diluted earnings per share-0.07-0.04-0.04-0.11-0.10-0.07-0.00-0.00
Total assets$2.2m$2.1m$2.1m$2.1m$2.1m$2.3m$2.2m$2.3m
Cash and short-term investments$145,258$44,801$45,043$30,740$26,905$218,263$19,534$36,840
Debt$1.4m$1.4m$1.4m$1.4m$1.4m$3.1m$1.4m$2.8m
Shareholders' equity−$6.4m−$6.3m−$6.1m−$5.9m−$5.3m−$5.0m−$4.9m−$4.5m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-30.4%-20.1%32.9%
Net income-25.1%-13.5%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2016FY2015
Price to earnings-1.6-301.9-156.0-26.7-23.4-14.71.1-0.0-0.00.0
Price to sales————————0.00.0

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return-22%116%99%-37%89%34424%1746%200%-50%100%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 150-to-1 reverse split · 23 Mar 2026
  • 50-to-1 reverse split · 23 Aug 2010
  • 10-for-1 split · 29 Nov 2007
  • 1000-to-1 reverse split · 29 Oct 2007
  • 1000-to-1 reverse split · 21 May 2004

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.